REGULATORY
Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo
The Central Social Insurance Medical Council, a health ministry panel better known as Chuikyo, on November 19 urged MSD K.K. to provide thorough information on the potential risk of narcolepsy associated with its insomnia drug Belsomra (suvorexant). Belsomra Tablets 15…
To read the full story
Related Article
- Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





